Florida Society of Clinical Oncology
Patient Centric Oncology Management
May 11, 2018 Tampa Marriott Waterside Hotel & Marina
Business of Oncology Summit│May 11, 2018
Patient Centric Oncology Management│Meeting Agenda
7:00-8:00 am REGISTRATION & BREAKFAST
Welcome & Thomas Marsland, MD Moderator Including Patients in 8:00-8:55 am Keynote Barbara McAneny, MD the Value Equation. Speaker President Elect, American Medical Association Thomas Marsland, MD Moderator What is meaningful in Lisa Shelar—Breast Cancer Survivor Oncology 9:00-10:00am oncology care to the Mike Schnider—Colon Cancer Survivor Patient Panel patient? Kathy Schnider—Caregiver Cynthia Schindele— Benefits Consultant, Lockheed Martin Karen Astley-Moore, RN, BSN, OCN - RN Cancer Guides Solutions 10:05-10:20am BREAK What have we learned Thomas Marsland, MD Moderator NCCN and 10:25-11:10am from NCCN Value Robert Carlson, MD Value Tools? National Comprehensive Cancer Network Rick McDonough, MD Moderator
Loretta Loftus, MD Practical Case Based Moffitt Cancer Center Cases Presented by: Examples of How Michael Diaz, MD Cesar Ochoa, MD Patient Centric Individual Practices 11:15-12:30pm Mayo Clinic Florida Tumor Board Assess and Address Florida Cancer Specialists the Wants and Needs Randal Henderson, MD, MBA Simon Abi Aad, MD of Each Patient. University of Florida University of Miami Magali Van den Bergh, MD Chris Gannon, MD Moffitt Cancer Center Memorial Healthcare System
12:30-1:30pm LUNCH
Patty Rea, Moderator How is industry Dean Alford Pharma Patient changing to a patient Genentech Dana Evans, MD 1:30-2:30pm Centric Panel centric business Fatima Scipione Genentech model and Takeda Oncology Matt Farber philosophy? Tom Croce Walgreens Non-CE Amgen Michael Diaz, MD Moderator
How are payers Eric Haas, MD 2:35-3:25pm Payer Panel addressing the shift to Florida Blue Juan Schaening, MD patient centric care? Jennifer Malin, MD, PhD First Coast Service Options United Healthcare
3:25 -3:30pm BREAK Thomas Marsland, MD Moderator Closing Key Empowering Cancer 3:35 –4:15pm Reverend Jason Micheli Note Speaker Patients. Author of Cancer is Funny 4:15 –4:30pm OPEN MIC AND Q&A│ADJOURN 2018 FLASCO
Business of Oncology Summit Friday, May 11, 2018
Thomas Marsland, MD Chairman
BIOGRAPHY: Dr. Tom Marsland is a practicing medical oncologist in Northern California. He has been in clinical practice for more than 30 years in a variety of practice settings.
Dr. Marsland graduated from Providence College, Rhode Island, and received his MD from Temple University in Pennsylvania where he also performed his internship and residency. He performed his fellowship in Oncology at Tufts New England Medical Center in Boston, and his fellowship in Hematology at University of Massachusetts. Dr. Marsland is board certified in Internal Medicine and Medical Oncology. After completing his fellowship, he moved to Jacksonville in 1980. In 1986 he participated in the development of the Orange Park Cancer Center.
Dr. Marsland has distinguished himself through years of leadership roles at the Orange Park Medical Center in Jacksonville, FL where he has been Chief of Staff and the American Cancer Society where he has been both the local and state Medical Director. He has served on the Board of Directors of both the American Society of Clinical Oncology and the Association of Community Cancer Centers. Dr. Marsland is a long time member of the Florida Society of Clinical Oncology where he has severed in many capacities including serving as President twice. Dr. Marsland is an Honorary Life Member of the American Cancer Society, Florida Division, Inc., and has served as President. He also was a very active member for several years of the National American Cancer Society.
Tom is married and has three grown children. He enjoys reading and travel with family and friends.
Joseph Bailes, MD Co-Chairman (Unable to Attend Summit)
BIOGRAPHY: Dr. Joseph S. Bailes is a medical oncologist with substantial experience in legislation, public policy and advocacy, as well as the business aspects of the practice of oncology and of medicine generally. For nearly two decades, Dr. Bailes served in various leadership capacities for the American Society of Clinical Oncology (ASCO). During his ten years as Chair of ASCO's Clinical Practice Committee, he led a number of legislative and regulatory initiatives that helped to shape the current environment for regulation and reimbursement of cancer care in the United States. He also oversaw the creation of ASCO's State/Regional Affiliates Program to enhance participation of community oncologists in the activities of the national organization. He served on the ASCO Board of Directors in the mid-1990's and was elected President of ASCO in 1999-2000. Subsequent to his Presidency, Dr. Bailes remained engaged in ASCO policy development.
For several years, he served as Chair of the ASCO Government Relations Council, a position that was responsible for ASCO's involvement in legislative, regulatory and public policy matters affecting cancer clinical research and treatment. During 2005 and 2006, Dr. Bailes was also involved in the day-to-day governance of ASCO as the Society's Interim Chief Executive Officer (CEO). During his tenure as Interim CEO, his responsibilities included budget and staffing oversight for both ASCO and the ASCO Foundation. Dr. Bailes served as Chair of the ASCO Foundation from 2007- 2009.
Dr. Bailes also has many years of experience in the practice of oncology in the private sector as a former partner in Texas Oncology, P.A., the largest oncology practice group in the country, and was a founding member of Physician Reliance Network (PRN), one of the corporate predecessors to US Oncology, Inc. Dr. Bailes served as President of PRN Research, where he oversaw clinical trials and drug development activities for the physician network. Subsequently, he was Executive Vice President for Clinical Affairs with US Oncology. He served on the Board of Directors of Ilex Oncology. In 2007, Dr Bailes was appointed to the Cancer Prevention and Research Institute of Texas (CPRIT) Oversight Committee by Texas House of Representatives Speaker Tom Craddick, serving until 2013.
Dr. Bailes received his medical degree from the University of Texas Southwestern Medical School at Dallas in 1981, followed by his internship and residency at Parkland Memorial Hospital in Dallas. He completed his Medical Oncology/Hematology Fellowship at the University of Texas Health Science Center in San Antonio in 1986. In 1994, the American Society of Internal Medicine named Dr. Bailes the Outstanding Young Internist of America. In addition to his private practice experience, Dr. Bailes has served as Clinical Assistant Professor at the University of Texas Health Science Center.
2018 FLASCO Business of Oncology Summit Moderators
Michael Diaz, MD Florida Cancer Specialists Immediate Past President, Florida Society of Clinical Oncology
BIOGRAPHY: Dr. Michael Diaz joined Florida Cancer Specialists & Research Institute (FCS) in 2011 and currently serves on the FCS Executive Board and as Director of Patient Advocacy for the practice. In addition, he serves on the Board of Directors and as Immediate Past President for the Florida Society of Clinical Oncology (FLASCO). Dr. Diaz also provides leadership on the Board of Directors for Community Oncology Alliance (COA), serving on the Payment Reform Task Force working to champion Medical Oncology Health Care Reform. He is active on the American Society of Clinical Oncology (ASCO) Payment Reform Work Group and was recently appointed to ASCO's Clinical Practice Committee. Dr. Diaz donates many hours as an active Medical Missionary and has participated in numerous medical missions to Kingston, Jamaica.
Rick McDonough, MD President, Florida Society of Clinical Oncology Florida Medical Clinic
BIOGRAPHY: Dr. Rick McDonough is from Clearwater and has lived most of his life in Florida. He is a proud graduate of the University of Florida. He enjoys bicycling, traveling, reading and spending time with his wife and three children. Dr. McDonough is a long standing active member of the Florida Society of Clinical Oncology and has proudly served on the board of directors for the past five years. Dr. McDonough contributes to the quality committee in his group, Florida Medical Clinic, a large multi specialty group in the greater Tampa area. Dr. McDonough is active in medical mission work, traveling every year with a group to Guatemala, providing primary care to a rural area in the Mountains northwest of Guatemala City since 2003.
Patricia Rea, RN Lilly Oncology
BIOGRAPHY: Working as an oncology nurse for over 25 years, Ms. Rea’s career has offered her the opportunity to experience the vast array of oncology care. Providing direct patient to hematology/oncology and bone marrow transplant patients and advancing to director of the gynecology oncology unit, she was involved in all levels of patient care at Indiana University Hospital. Managing the nursing staff and providing OSHA oversight at Hematology Oncology of Indiana, she experienced the full spectrum of outpatient oncology care, including mixing and administering chemotherapy as well as creating drug protocols while managing the overall responsibility of patient care at the main clinic as well as the satellite offices. Continuing her career at Eli Lilly and Company, she began as research coordinator for oncology drug development. She has since held several positions offering a broad range of experiences from performing as a regional research coordinator, marketing associate, compliance officer, new product planning associate to her current position as a senior key account manager. Throughout her career it is her passion as a patient advocate that drives her ambitions and her desire to improve the cancer care experience.
Including Patients in the Value Equation
Barbara L. McAneny, MD, FASCO, MACP President-elect American Medical Association
BIOGRAPHY: Barbara L. McAneny, MD, a board-certified medical oncologist/hematologist from Albuquerque, N.M., was elected president-elect of the American Medical Association in June 2017. Dr. McAneny served as chair in 2015–2016. An impressive leader, Dr. McAneny has been a member of the American Society of Clinical Oncology (ASCO) Board of Directors, president of the New Mexico Medical Society (NMMS), president of the Greater Albuquerque Medical Association, and president of the New Mexico Chapter of the American College of Physicians.
Currently Dr. McAneny chairs the board of the National Cancer Care Alliance, which she founded to help independent oncology practices compete by sharing resources and best practices. A fellow of both the ASCO and master of the American College of Physicians, she became the delegate to the AMA from the ASCO in 2002, and was elected to the AMA Council of Medical Service in 2003, serving as its chair in 2009–2010.
Dr. McAneny was appointed to the Practicing Physicians Advisory Council from 2002 to 2006 and was a founding member of Oncology Circle, a group of oncology practices using data to promote best practices. She is also a member of the Community Oncology Alliance Board of Trustees and served on the board of directors of the Cancer Center Business Summit. She has previously Chaired Albuquerque’s EMS Authority for ten years, from 1990 – 2010.
In 2012 Dr. McAneny received a $19.8 million award from the Centers for Medicare & Medicaid Innovation to test how oncology private practices could provide cancer patients better care at a lower cost. This award, called COME HOME (for Community Oncology Medical Home), later helped form Medicare’s Oncology Care Model. Innovative Oncology Business Solutions Inc., the company she created to manage the award, is now assisting physician practices in developing the process changes needed for MACRA.
Among other volunteer activities, she has served on the governor of New Mexico’s Task Force on Prenatal Care, the board of Planned Parenthood of New Mexico, and as chair of the joint task force of the NMMS and the New Mexico Bar Association on domestic violence. A recipient of a New Mexico Woman on the Move Award in 2005 and Woman of Influence Award in 2009, Dr. McAneny has been voted several times by her peers as Albuquerque The Magazine’s “Top Doc” in her specialty.
She co-founded New Mexico Oncology Hematology Consultants Ltd. in 1987. A managing partner since 1999, she built New Mexico Cancer Center, which provides outpatient medical and radiation oncology care and imaging at multiple sites, including several underserved areas. She also founded the New Mexico Cancer Center Foundation, which provides grants to help patients with nonmedical expenses.
Dr. McAneny graduated magna cum laude from the University of Minnesota in 1973 and with honors from the University of Iowa College of Medicine in 1977. She completed her residency in internal medicine at the University of Iowa in 1980 and her fellowship in hematology/oncology at the University of New Mexico in 2003. Oncology Patient Panel
Lisa Shelar Breast Cancer Survivor, 21st Century Oncology BIOGRAPHY: Lisa Shelar, holds a RHIT certification and her degree is in Health Information Management. She has been active with numerous organizations including, Leukemia and Lymphoma Society, North Florida Uninsured Work Group and North Florida Cancer Collaborative. Lisa has been employed with 21st Century Oncology since August 2013 and currently is the Physician Liaison for 9 offices and 14 providers. Lisa has been married for 30 years and has 3 children, 3 grandchildren and a fabulous "Senior Willy" who is a 9 pound Maltese. She was diagnoses with Breast Cancer in March of 2017 and underwent surgery, chemo , radiation and reconstructive surgery.
Karen Astley-Moore, RN, BSN, OCN Oncology Nurse Navigator, RN Cancer Guides BIOGRAPHY: Karen Astley-Moore, RN, BSN, OCN, CMCN is currently a Nurse Navigator with RN Cancer Guides Solutions headquartered here in Tampa, Florida. Karen has 35 years of experience in the oncology healthcare environment, including oncology nursing, pharmaceutical and consulting industries. Karen’s unique background provides her with the ability to understand the needs of the patient, physician, nurse, manufacturer and payer. Throughout her career, Karen has thrived to improve the cancer care experience for patients and their loved ones, as well as oncology healthcare providers. Karen's oncology clinical expertise includes direct patient management, as well as management of hospital outpatient and private oncology practices. She has held various management positions including recruitment and management of clinical trials; nursing management; oncology case management; development and coordination of a multidisciplinary lung cancer program and development and implementation of an Oncology Navigation and Survivorship program. Karen has extensive experience as a national speaker for numerous biopharmaceutical companies and served as Past President and Director-at-Large for the South Jersey Oncology Nursing Society.
Mike Schnider Colon Cancer Survivor BIOGRAPHY: Mike Schnider is surviving with metastatic colon cancer. Mike comes from the construction industry where he was a swimming pool contractor.
He is now involved with the “Cancer Care Foundation of Brevard” where he volunteers and sits on the Board of Directors. He has been married for 31 years, has 2 children and 2 grandkids. He was diagnosed in 2012 with stage 4 colon cancer, had resection surgery, did the six months of chemo. The cancer returned in 2014 as metastatic colon cancer and he is currently on a lifelong maintenance program.
Kathy Schnider Caregiver BIOGRAPHY: Kathy is currently a financial counselor at the Cancer Care Centers of Brevard. She has been in the medical field for 40 plus years, as a medical assistant, radiology technician & most recently has worked as a patient account representative. She is also a full time wife, Mother & Grandmother.
She and Mike have been married 31 years and have 2 amazing children, a son Mike and a Daughter, Kaitlyn. Their son and his wife Casey have blessed them with their first Grandson, Colton. Their daughter Kaitlyn and her husband Robert blessed them with their first Granddaughter, Patricia. They are so thankful for each day and their amazing family.
NCCN and Value
Robert W. Carlson, MD Chief Executive Officer National Comprehensive Cancer Network
BIOGRAPHY: Robert W. Carlson, MD, is the Chief Executive Officer at the National Comprehensive Cancer Network (NCCN). He joined NCCN as CEO in January 2013 following an esteemed history of leadership positions within the organization including, most notably, Representative to the NCCN Board of Directors, Chair of the Breast Cancer Guidelines Panel, Member and Founding Chair of the Breast Cancer Risk Reduction Guidelines Panel. and Chair of the Survivorship Guidelines Panel.
Prior to his appointment as CEO at NCCN, Dr. Carlson served as Professor of Medicine in the Division of Oncology and Stanford Medical Informatics at Stanford University Medical Center, as well as Medical Director of inpatient oncology and hematology at Stanford Cancer Institute in California.
Dr. Carlson is a graduate of Stanford University Medical School, and he completed his internship and junior residency in internal medicine at Barnes Hospital Group in St. Louis before returning to Stanford University to complete his senior residency. He earned a Bachelor of Science with distinction from Stanford University, specializing in biological sciences. Dr. Carlson is board certified in Medical Oncology and Internal Medicine.
Patient Centric Tumor Board
Loretta Loftus, MD, MBA Senior Member with Tenure Professor of Medicine Department of Breast Oncology Moffitt Cancer Center & Research Institute BIOGRAPHY: Dr. Loretta Loftus is a medical oncologist and a senior member in the Department of Breast Oncology at Moffitt Cancer Center. Dr. Loftus is Moffitt’s principal investigator of the National Comprehensive Cancer Network Breast Outcomes Project, which is a national database and resource for best practice decisions. She is also a member of the NCCN panel for breast cancer risk assessment and reduction. Dr. Loftus helped develop Moffitt’s Lifetime Cancer Screening Center high risk breast clinic for women at increased risk based on family history. She is actively involved in patient care, teaching and research activities, and is a member of numerous regional, national and international medical organizations. In addition to her research in breast cancer, Dr. Loftus participates in studies related to geriatric cancer and is a member of the International Society of Geriatric Oncology. The art and humanistic side of medicine interests Dr. Loftus. She has lectured frequently on this topic and on the life, art and illness of well-known public figures, such as writer Sylvia Plath and artists Vincent Van Gogh and Georgia O’Keefe. Dr. Loftus has an MBA from the University of South Florida and is a member of the Mystery Writers of America. She is currently working on a mystery novel.
Michael Diaz, MD Community Oncology Alliance Vice-President Florida Cancer Specialists Director of Patient Advocacy Florida Society of Clinical Oncology Immediate Past President Florida Society of Clinical Oncology Director of Patient Advocacy Florida Cancer Specialists and Research Institute BIOGRAPHY: Dr. Michael Diaz joined Florida Cancer Specialists & Research Institute (FCS) in 2011 and currently serves on the FCS Executive Board and as Director of Patient Advocacy for the practice. In addition, he serves on the Board of Directors and as Immediate Past President for the Florida Society of Clinical Oncology (FLASCO). Dr. Diaz also provides leadership on the Board of Directors for Community Oncology Alliance (COA), serving as the Vice President. He is active on the American Society of Clinical Oncology (ASCO) Payment Reform Work Group and has served on ASCO's Clinical Practice Committee. Dr. Diaz donates many hours as an active Medical Missionary and has participated in numerous medical missions to Kingston, Jamaica.
Randal Henderson, MD, MBA University of Florida BIOGRAPHY: Dr. Henderson has more than 25 years experience as a radiation oncologist and is board certified in therapeutic radiology. A UF faculty member and physician at UF & Shands Jacksonville since 1998, he has led the Department of Radiation Oncology at Shands Jacksonville as its medical director, associate chairman and since 2006 as associate medical director of the UF Proton Therapy Institute. Dr. Henderson’s expertise includes prostate cancer as well as gynecologic malignances. He is the Principal Investigator on five prospective prostate cancer trials conducted at the UF Proton Therapy Institute. Dr. Henderson is a past President and current member of the board of directors for the Florida Society of Clinical Oncology. He is a member of American Society of Therapeutic Radiology and Oncology, and the American Society of Clinical Oncology.
Chris Gannon, MD Medical Director of Surgical Oncology, Surgical Oncology and Hepatobiliary Surgeon Memorial Health System
BIOGRAPHY: Dr. Gannon completed his undergraduate education at Yale University. He received his medical degree from Columbia University College of Physicians & Surgeons. He then completed training in general surgery at the University of Maryland in Baltimore. His surgical oncology fellowship was completed at M.D. Anderson Cancer Center in Houston, Texas. He currently serves as Medical Director of Gastrointestinal Oncology and Surgical Oncology at the Memorial Health System. Dr. Gannon’s clinical practice is focused on the treatment of liver, pancreatic, and gastric malignancies. Additionally, he treats colorectal cancers, soft tissue sarcomas, and cutaneous malignancies.
Case Presentations Cesar Ochoa, MD Mayo Clinic Florida BIOGRAPHY: Dr. Ochoa is a Hematology/Oncology Fellow at Mayo Clinic. He received his medical degree from Tecnologico de Monterrey School of Medicine in Monterrey, Mexico. His postgraduate training includes an Internal Medicine Residency at Wayne State University – Henry Ford Health System in Detroit, MI and a Postdoctoral Research Fellowship at MD Anderson Cancer Center in Houston, TX where he studied the innate immune signaling pathways and focused on the role of IL-6/STAT3 on a KRAS-mutant model of lung carcinogenesis. Dr. Ochoa is currently involved in identifying markers of response to immunotherapy in NRAS-mutant melanoma and the development of a model that incorporates immune checkpoint blockade to intraperitoneal chemotherapy for the treatment peritoneal carcinomatosis from colorectal and ovarian cancer. His career interests include translational research and solid tumor immunotherapy.
Simon Abi Aad, MD University of Miami BIOGRAPHY: Dr. Simon Abi Aad is a 3rd year fellow in the Hematology and Medical Oncology Fellowship Program, Jackson Memorial Hospital/Jackson Health Systems, Miami, Florida. Dr. Abi Aad began his first year of training on July 1, 2015 and is expected to complete his training June 30, 2018. He received his doctor of medicine degree at the Universite Saint Esprit de Kaslik Faculte de Medecine et des Sciences Medicales, Jounieh, Lebanon 09/2002 – 06/2009. He continued his education at the Icahn School of medicine at Mount Sinai, in New York, 07/2015. He received his American Board of Internal Medicine Certification 08/2015, when he also obtained his New York State Medical License. He is a member of ASCO and ASH. He has noted that he is willing to serve as a FLASCO Board Appointee and also on the Bylaws, Clinical Practice, Ethics, Legislative, and Program Committees.
Magali Van den Bergh, MD Moffitt Cancer Center
BIOGRAPHY: Dr. Magali Van den Bergh is a Belgian native who graduated from Northwestern State University with a dual degree in Biology and Chemistry, while competing in Division I college tennis. She obtained her medical degree at American University of the Caribbean and completed her internal medicine training at University of Connecticut. She is currently a third year hematology/oncology fellow at Moffitt Cancer Center.
Throughout her medical training, Dr. Van den Bergh has served in several leadership roles; she currently serves as the FLASCO medical oncology fellow liaison and is the chief fellow at Moffitt Cancer Center. She has an interest in benign and malignant hematology and is actively involved in clinical research focusing on lymphoproliferative disorders. She has published a number of peer-reviewed articles with presentations at national and international meetings. Dr. Van den Bergh will be joining Florida Cancer Specialists in Fort Myers upon completion of her fellowship.
Pharma Patient Centric Panel
Dean Alford Vice President of Patient Support Services Genentech
BIOGRAPHY: Dean Alford has been with Genentech since 2001 and is currently the Vice President of Genentech Access Solutions. Access Solutions is responsible for helping Genentech patients start and stay on therapy through industry leading people and services. Access Solutions has helped over 1.5 million patients since its inception and is responsible for over 250,000 patient interactions annually. During his tenure at Genentech, he has held various positions including Sales, Marketing, Strategic Analytics & Operations. Prior to joining Genentech, Dean was Senior Vice President Hospital Operations at Quorum Health Resources where he was responsible for operational activities related to the physician outpatient and medical staff services for a 120-bed community hospital. Dean graduated with a Bachelor of Science degree in Marketing Management from the University of Arkansas, Fayetteville. Outside of work he enjoys spending time with his wife Catharine and two children, Zach (18) and Abby (16).
Fatima Scipione Senior Director of Patient Advocacy Takeda Oncology
BIOGRAPHY: Fatima Scipione is Senior Director, Patient Advocacy, for Takeda Oncology a position she has held since September, 2015. In her current role, Fatima leads an internal patient advocacy department that is responsible for creating and sustaining strategic programs with key patient groups within the oncology sector. These novel initiatives include those that address the current needs and issues that are crucial to cancer patients, including research, therapeutic, economic and access. Prior to her current position, Fatima held a series of senior management positions within select pharmaceutical and healthcare organizations during a career that has spanned two decades. These included Associate Director, Takeda Pharmaceuticals; Vice President, Brand Strategy, Mc/K Healthcare; Market Development Manager, ARIAD Pharmaceuticals; and Senior Manager, Market Strategy, Millennium Pharmaceuticals. Fatima was also named to the PharmaVOICE 100 in 2014 in the category of patient advocacy and a recipient of the 2015 Trailblazer Brand Champion Award from PM360.
Tom Croce Vice President, Global Advocacy Relations Amgen
BIOGRAPHY: Tom, a pharmacist by training, is an Advocacy and Public Affairs executive with clinical practice experience and record of success in creating opportunities to advance advocacy, policy and commercial objectives. He currently directs a function focused on aligning business objectives with a myriad of patient advocacy and professional organizations in diverse therapeutic areas, to bring value to the business, the organizations, and to patients. His background in practice in hospital, community and institutional care pharmacy provides unique perspective on healthcare system issues. He has expertise in advocacy and alliance development, public policy, issues management, strategy and business planning, and opinion leader and trade relations.
Dana Evans, MD Director for Patient Access, Collaboration and Exchange Genentech
BIOGRAPHY: Dana Evans is the Director for Patient Access, Collaboration and Exchange with Genentech Medical Affairs. Dr. Evans manages a team of clinicians that provides scientific, clinical and managed care professional support to account teams who are responsible for payers, hospitals, government programs, group purchasing organizations and product distribution companies.
Dr. Evans obtained his medical degree from the University of Texas Medical School at Houston and completed his residency in Family Medicine at Southwest Memorial Hospital in Houston. He practiced family medicine in Texas, including obstetrics and surgery, for seven years. In 1992, he left clinical practice to begin a career in administrative medicine. His resume includes positions as medical director, chief medical officer and executive officer for regional and national health plans. He has also been a managed care consultant for health plans and physician organizations. He moved to the pharmaceutical industry as a medical director for managed care with GlaxoSmithKline in 2001. Dr. Evans joined Genentech in 2008 as a medical director for Value Based Healthcare.
Matt Farber Senior Director, Oncology Disease State Management Walgreens BIOGRAPHY: Matt Farber is the Senior Director, Patient Care and Advocacy for Oncology & Fertility for Walgreen Co. In this role, he is responsible for the development and implementation of the national oncology and fertility strategies. For over 3 years, Matt has worked with all external partners, including: providers, patients, caregivers, pharmaceutical companies, payers, and employers in identifying how best Walgreens can be a partner in the delivery of quality cancer and reproductive health care. Matt also works with external partners like: the Leukemia and Lymphoma Society (LLS), the Oncology Nursing Society (ONS), and others on the overall message development. Prior to joining Walgreens, Matt worked for almost 10 years with the Association of Community Cancer Centers (ACCC) on issues relating to the policy and economics of cancer care. Matt graduated with a Masters degree in Political Management from The George Washington University, as well as his BA in International Affairs from The George Washington University.
Payer Panel
Eric Haas, MD Medical Director of Clinical Affairs Florida Blue
BIOGRAPHY: Dr. Haas is Florida Blue’s Senior Medical Director of Clinical Affairs. In this role, Dr. Haas is Clinical Lead for Healthcare Innovations. Dr. Haas is a physician leader with over twenty years of clinical, hospital, pharmaceutical and managed care experience. A native of Philadelphia, Pennsylvania, Dr. Haas earned his Bachelor of Science degree from Kent State University and his Medical Doctorate from Northeastern Ohio Universities College of Medicine. He then completed his Family Medicine Residency at Abington Memorial Hospital in Abington, Pennsylvania. Upon completion of training Dr. Haas practiced two years in Washington, D.C. Dr. Haas remains actively Board Certified in Family Medicine since 1988. After relocating to Florida, Dr. Haas served as managing partner of his six doctor Family Practice group. Once his practice merged into a Physician Hospital Organization, he was elected Chairman of Board of this 150 doctor organization. Post 12 years in clinical practice Dr. Haas transitioned into pharmaceutical research and then managed care. As the Senior Regional Medical Scientist of Glaxo Dr. Haas was responsible for setup of phase 3 & 4 research studies, development of key thought leaders and interface with manage care on pharmacoeconomics. Next in his career track Dr. Haas took on the role of Network Medical Director and Aetna/Prudential serving a commercial population then onto WellCare Health Plans where he oversaw the Medicare and Medicaid population. In these roles Dr. Haas was responsible for improvement in quality, as well as cost of medical care. He also was instrumental in NCQA and AAAHC accreditations and Aetna and WellCare respectively. Prior to joining Florida Blue, Dr. Haas served as Vice President of Clinical Affairs of FPG/ Family Physicians Group where he provided Medical Director Leadership to a 90 doctor MSO in Central Florida.
Jennifer Malin, MD, PhD Senior Medical Director of Oncology and Genetics UnitedHealthcare
BIOGRAPHY: Jennifer Malin, M.D., Ph.D., is a Senior Medical Director, Oncology and Genetics, at UnitedHealthcare. In this role, she provides clinical and strategic leadership for improving the health and outcomes of UnitedHealthcare members with cancer. After graduating from Harvard University, Dr. Malin received her medical degree and doctorate in public health from UCLA. She is board certified in internal medicine and medical oncology. A Clinical Professor of Medicine at the UCLA David Geffen School of Medicine, she is the author of more than 90 peer-reviewed articles and is widely recognized for her research on the quality of cancer care. She has served on a number of advisory boards and national committees, including the American Society of Clinical Oncology’s Quality of Care Committee and the National Quality Forum’s Cancer Steering Committee. Prior to joining UnitedHealthcare, she was the architect of the cancer care quality program at Anthem.
Dr. Malin continues her clinical practice by volunteering at the Veterans Affairs Greater Los Angeles Health Care System. She lives in Santa Monica, California with her two children and three dogs.
Juan Schaening, MD Contractor Medical Director First Coast Service Options
BIOGRAPHY: Juan L. Schaening Perez, MD is a Contractor Medical Director for the Jurisdiction N Medicare Administrative Contractor. The Jurisdiction N MAC issues annually 19.5 billion dollars of Medicare Part A and Part B benefit payments for Florida, Puerto Rico and the Virgin Islands. Dr. Schaening has occupied for the past thirteen years the position of Puerto Rico Medicare Medical Director. He is a past Chief Medical Director of the Puerto Rico Correctional Health Service Program.
Dr. Schaening obtained his M.D. from the University Of Puerto Rico School Of Medicine. He specialized in Internal Medicine at the Department of Health University Hospital in Puerto Rico. He has a Bachelor degree in Biology from the University of Puerto Rico where he did research in the field of cellular molecular biology through a scholarship from the Minority Access for Research Careers Honor Program.
Empowering Cancer Patients
Reverend Jason Micheli Executive Pastor, Aldersgate United Methodist Church Author Cancer Survivor
BIOGRAPHY: Jason Micheli, a young father, husband, and pastor, was diagnosed with a bone cancer so rare and deadly that his doctors didn't classify it with one of the normal four stages, they simply called it "stage-serious." As Micheli struggled with despair and faced his own mortality, he resolved that although cancer kills the body, it would not kill his spirit, faith, or sense of humor.
Micheli knew that the promise of faith makes hope possible. Micheli's story teaches us all how to stay human in dehumanizing situations and how to keep living in the face of death.
2018 FLASCO SPRING SESSION
May 11 & 12, 2018
ACCREDITATION STATEMENTS
Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical Educator Consortium and Florida Society of Clinical Oncology. The Medical Educator Consortium is accredited by the ACCME to provide continuing medical education for physicians.
Designation Statement: The Medical Educator Consortium designates this live activity for a maximum of 9 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Statement: The Medical Educator Consortium (MEC) adheres to the ACCME Standards for Commercial Support. All persons that will be in a position to control the content of the CME Activity are required to disclose all relevant financial relationships. Faculty disclosure forms outlining this information will be made available to all participants prior to educational activity. MEC has also implemented a mechanism to identify and resolve all conflicts of interest prior to the educational activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity.
The Leukemia & Lymphoma Society
Approval for nurses has been obtained by the Southern Florida Chapter of The Leukemia & Lymphoma Society under provider number 50-12996 (Expiration Date: 10/31/2018) to award up to 9.0 contact hours through the Florida Board of Nursing.
Memorial Regional Hospital The FLASCO Spring Meeting for MEMORIAL REGIONAL HOSPITAL developed and presented for Florida Board of Pharmacy professionals has been approved and registered for 9.0 contact hours. FACULTY DISCLOSURE (onsite distribution)
2018 FLASCO SPRING SESSION May 11th – May 12th, 2018 Tampa, FL
The Medical Educator Consortium in accordance with the Standards of Commercial Support of the Accreditation for Continuing Medical Education (ACCME), will disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services by anyone in control of content.
As a CME provider decisions in the planning process of this conference were made free of the control of commercial interests. All individuals who are in a position to control the content of this educational activity have disclosed all relevant financial relationships with any commercial interest to the provider. In accordance with the CME Provider’s Conflict of Interest & Resolution Policy, any conflict of interest pertaining to this CME Activity have been resolved. This disclosure includes any all persons in control of content to include staff and educational committee members involved in the planning process.
The current definition reads: "A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients."
Speakers FLASCO Spring Session Agenda Rick McDonough Other: Bayer Barbara McAneny Has no relevant financial relationships Craig Lockhart Has no relevant financial relationships Krishna Komanduri Consultant: Kite, Novartis, Juno, Sanofi, KKD Luis Raez Grant/research: BMS, Merck, Pfizer, AstraZeneca, Syndax, Genentech Edgardo S. Santos Speakers Bureau: Genentech, Lilly, Celgene, Millennium, Amgen, AstraZeneca, Merck, Boehringer Ingelheim Jarushka Naidoo Has no relevant financial relationships
Speakers – Business of Oncology Session Simon Abi Aad Grant/Research: Florida Breast Cancer Foundation Robert Carlson Has no relevant financial relationships Barbara McAneny Has no relevant financial relationships Lisa Shelar Has no relevant financial relationships Mike Schnider Has no relevant financial relationships Kathy Schnider Has no relevant financial relationships Cynthia Schindele Has no relevant financial relationships Loretta Loftus Stock shareholder: Amgen, Eli Lilly, Pfizer, Merck, Johnson & Johnson, Gilead Michael Diaz Consultant: Janssen Oncology, OTH Healthcare Group John Eric Haas Has no relevant financial relationships Randal Henderson Has no relevant financial relationships Chris Gannon Has no relevant financial relationships Jennifer Malin Stock Shareholder: United Healthcare Jason Micheli Has no relevant financial relationships Thomas Marsland Stockholder: J&J, Novartis, Seattle Genetics, Kythera Bio, BMS, Consultant: Alexion Pharma; Genentech/Roche Juan Schaening Has no relevant financial relationships 1
Cesar Ochoa Has no relevant financial relationships Magali Van Den Bergh Has no relevant financial relationships Karen Astley-Moore, RN Consultant: Lilly Oncology, Amgen Speakers’ Bureau: Lilly Oncology
Planning committee Luis Raez Grant/research: BMS, Merck, Pfizer, AstraZeneca, Syndax, Genentech Edgardo S. Santos Speakers Bureau: Genentech, Lilly, Celgene, Millennium, Amgen, AstraZeneca, Merck, Boehringer Ingelheim Seth Berkowitz Has no relevant financial relationships Gerardo Colon Grant/Research: Novartis to Mayo Clinic Ardeshir Hakam Consultant: Womens’ Care Florida Jorge Garcia Has no relevant financial relationships Eric Harris Consultant: BMS, Novartis Speakers Bureau: BMS, Novartis Amgen Mayra Lima Speakers Bureau: Pfizer Rick McDonough Other: Bayer Brendan Prendergast Consultant: Orano Med. Joseph Rosenblatt Grant/Research: Synergys. Consultant: Mologen, Merck Jose Sandoval Sus Has no relevant financial relationships Winston Tan Has no relevant financial relationships Beau Toskich Consultant: Johnson & Johnson, BTG, Scientific, New Wave Katerina Williams Has no relevant financial relationships Julie Newberry Has no relevant financial relationships Dorothy Phillips Has no relevant financial relationships Shannon Luker Has no relevant financial relationships Amanda Bridges Has no relevant financial relationships Joe Bailes Consultant: Jazz, Lilly, Genomic Health Teri Valls Has no relevant financial relationships (CME provider)
CME reviewer Edgardo S. Santos Speakers Bureau: Genentech, Lilly, Celgene, Millennium, Amgen, AstraZeneca, Merck, Boehringer Ingelheim Teri Valls Has no relevant financial relationships (CME provider)
Each speaker will directly disclose the use of products for which are not labeled (e.g., off label use) or if the product is still investigational.
ALL SPEAKERS HAVE BEEN REQUESTED TO VERBALLY DISCLOSE PRIOR TO THEIR PRESENTATION AND TO KEEP THEIR PRESENTATION UNBAISED AND GENERIC WHEN APPLICABLE.
2
2018 DIAMOND ELITE CORPORATE MEMBERS Alexion Amgen AstraZeneca Bristol– Myers Squibb Celgene Genentech Merck Pfizer Oncology Takeda Oncology Teva Pharmaceuticals
Current as of 4/5/18 2018 DIAMOND CORPORATE MEMBERS
Astellas Pharma
Bayer
Boehringer Ingelheim
EMD Serono
Lilly Oncology
Pfizer Biosimilars
Sandoz
Sanofi Genzyme
Seattle Genetics
Current as of 4/5/18 18 20 FLASCO CORPORATE MEMBERS
AbbVie Adaptive Biotechnologies Eisai enterade® Exelixis Foundation Medicine Gilead Sciences Ipsen Guardant Health Heron Biopharmaceuticals Therapeutics Novartis Agios Pharmaceuticals Incyte Biodesix INSYS Therapeutics Clovis Oncology Johnson & Helsinn
Johnson Kroger Specialty Kite Pharma Pharmacy NanoString Lexicon Oncology Supply/ Pharmaceuticals ION Solutions Novocure Pharmacyclics Spectrum Puma Biotechnology Pharmaceuticals Sun Pharma Sysmex Taiho Oncology TerSera Walgreens Therapeutics TESARO Updated as of 4/19/18 FLASCO Business of Oncology
May 11, 2018
ROSTER OF ATTENDEES
Simon Abi Aad MD Japneet Bedi Tim Carr University of Miami Takeda Oncology Bristol-Myers Squibb
Syed Abid MD, FACP Jerry Beer Robert Cassell MD, PhD Pinellas Hematology & Pfizer Biosimilars Oncology, PA Chakra Chaulagain MD, Peter Benavente FACP Robert Adams Teva Oncology Cleveland Clinic AbbVie Patricia Benjamin Perry Chohan Peter Adeosun BSc, MS Boehringer Ingelheim AstraZeneca University of Florida College of Pharmacy Barry Berman MD Steve Cobb University of Miami Seattle Genetics Robin Adley RN Martin Health System Scott Best Cathryn Connelly RN, BS, Astellas OCN Tiba Al Sagheer PharmD Martin Health System Mayo Clinic Florida Robert Bexley Celgene Frank Craft Michael Alford Sanofi Genzyme Oncology Genentech Lea Ann Biafora MS, RN, OCN, CCM Thomas Croce Jr., RPh Judith Allen PharmD Humana Amgen Florida Hospital Amanda Bridges Paul Cruz Ollie Anum PharmD FLASCO Merck Oncology
Avan Armaghani MD Scott Brock Vivian Curran RN, MSN University of Florida Bristol-Myers Squibb Sanofi Genzyme Oncology
Robert Armenia Lauren Brod Arleen DeCicco Astellas Takeda Oncology Syndax Pharmaceuticals
Ralphy Arriaga Christopher Bryant MD Mark Demps Takeda Oncology Women's Care Florida Pfizer Oncology
Karen Astley-Moore RN Jacquie Buckley Heather DeRue-Biddle RN Cancer Guides Takeda Oncology IPSEN
Annette Avicolli PharmD Leah Burdett Pratibha Desai MD, MPH Novartis Oncology Takeda Oncology Pinellas Hematology & Oncology, PA Joseph Bailes MD Denise Capo Helsinn Therapeutics Michael Diaz MD Christy Banach Florida Cancer Specialists Florida Cancer Specialists Leo Cardona Eisai Dawn Dolan PharmD Suzette Bannister Merck Oncology Novartis Oncology Robert Carlson MD National Comprehensive Dora Dopico Kelly Batista MHA Cancer Network Eisai Sarasota Memorial Hospital
(Current as of April 25, 2018) Business of Oncology Attendees - Continued Keith Douglas Jorge Garcia PharmD, MS, John Eric Hass MD Spectrum Pharmaceuticals MBA Florida Blue Memorial Healthcare System Chad Due Randal Henderson MD, MBA Bayer Faithlore Gardner MD University of Florida Health Florida Cancer Specialists Proton Therapy Institute Dina Dumercy PharmD, BCOP, BCPS Chanda George Chad Henley Memorial Cancer Institute Teva Oncology Pfizer Oncology
Nikki Earnest RN Cliff Gindin Chad Henley Novartis Oncology Sandoz Pfizer Oncology
Hany Edward PharmD, MS Scott Gingrich Sarah Hennemann US Food & Drug AstraZeneca Florida Hospital Cancer Administration Institute Shelly Glenn Chris Edwards Florida Cancer Specialists Lee Hennigan Lexicon Pharmaceuticals Novartis Oncology Amy Gomez Paul Edwards Boehringer Ingelheim Amyn Hirji Merck Oncology Helsinn Therapeutics Glen Greenwood Gail Erentreich Bristol-Myers Squibb Terry Hofmann Cancer Care Centers of Helsinn Therapeutics Brevard Adam Grennan Amgen Mellisa Holder-Utkovic Alvaro Estrada MBA Amgen Sanofi Genzyme Oncology Bradley Gwirtz Alexion Kathy Holmes Dana Evans MD TESARO Genentech Rob Haefeli Alexion Terrilyn Holtkamp RN Jimmy Evans Parrish Medical Center Seattle Genetics Mintallah Haider MD Moffitt Cancer Center Tony Honingford Matthew Farber Genentech Walgreens Co. Ardeshir Hakam MD, MBA Moffitt Cancer Center Sarah Hopkins Steven Fein MD Johnson & Johsnon: Janssen Miami Cancer Institute Dale Hansen Oncology Sanofi Genzyme Oncology Kevin Feldman Michael Houser Oncology Supply Sarah Hanson Boehringer Ingelheim Pfizer Oncology Karen Fields MD Becky Howe Moffitt Cancer Center Holly Hanzlik Amgen Seattle Genetics Sergio Fleites Michelle Hudson Array Biopharma Dave Harris Lilly Oncology Amgen Christopher Gannon MD, Donna Huffstater FACS Eric Harris DO Merck Oncology Memorial Physicians Group Florida Cancer Specialists Sarah Hughes Amgen
(Current as of April 25, 2018) Business of Oncology Attendees - Continued Susie Hultgreen RN Christofer Kemp Jennifer Malin MD, PhD Parrish Medical Center AbbVie UnitedHealthcare
Emily Hurley RN Keith Kempka Adrianne Mallen MD Parrish Medical Center Amgen Moffitt Cancer Center
Todd Hutson Robin Kennedy Kelly Markey EMD Serono Pfizer Oncology Celgene
Kankendria Ingram Farah Khalil MD, FCAP Alan Marks MD Merck Oncology Moffitt Cancer Center A R Marks Consulting LLC
Steve Ingram Waseem Khan MD Thomas Marsland MD Teva Oncology Cancer Care of North Florida Leyner Martinez PharmD, Kirsten Ireson Shaunna Kobilis MS, MHA Eisai Adaptive Biotechnologies Joe DiMaggio Children's Hospital Mohammad Jahanzeb MD, Tim Kress FACP Merck Oncology Jane Mascola University of Miami, Pfizer Oncology Sylvester Marie Lafosse PharmD Memorial Cancer Institute Barbara McAneny MD Dawn Javino PharmD American Medical Merck Oncology Richard Lancellot Association Boehringer Ingelheim Dominique Jean-Baptiste Scott McCallum RN, BSN Susan Langford Pharmacyclics Broward Health Coral Amgen Springs Richard McDonough MD Stacey Larrison Florida Medical Clinic Kun Jiang MD Takeda Oncology Moffitt Cancer Center Claire Meci Joe Lehmer Amgen Richard Johnson Bristol-Myers Squibb Takeda Oncology Denise Meyer Deanna Leschinski Bristol-Myers Squibb Shelli Johnson Eisai Cancer Care Centers of Wayne Meyerson Brevard Xiomara Lever Seattle Genetics Astellas Scott Jorgensen Jason Micheli Incyte Richard Levine MD Aldersgate United Methodist Moffitt Cancer Center Church Brad Kalkwarf Amgen Chris LoBiondo Joseph Mignone MD American Society of Clinical 21st Century Oncology Janyce Kamahele Oncology Eisai Arjun Mittra MD, MBBS Loretta Loftus MD Mayo Clinic Florida Lisa Kaschak Moffitt Cancer Center Astellas Nikkiann Molner Shannon Luker RN, OCN, Amgen Kathryn Keith CBCN Merck Oncology Parrish Medical Center Donna Moncuso MS, RN NCCN
(Current as of April 25, 2018) Business of Oncology Attendees - Continued Anay Moscu PharmD Marianna Polonsky Ashley Salvesen Moffitt Cancer Center Foundation Medicine Merck Oncology
Rhory Moss Herman Powery II PharmD Jose Sandoval-Sus MD Incyte Memorial Regional Hospital Moffitt Cancer Center/Memorial Healthcare Mark Mularski Brendan Prendergast MD System AbbVie Health First Cancer Institute Liz Santarsiero MSN, ARNP Rebecca Murphy Dusti Prisock Novartis Oncology Sysmex-Inostics Kite Pharma Edgardo Santos MD, FACP Siva Murthy Louanne Provonsha Lynn Cancer Institute Merck Oncology Novartis Oncology Greg Sargent Zeina Nahleh MD Ian Qureshi DO, PhD Sanofi Genzyme Oncology Cleveland Clinic Larkin Community Hospitl Tony Savine Ed Newhouse Patty Rae Pfizer Oncology Pfizer Oncology Lilly Oncology Juan Schaening MD Judy Nguyen Luis Raez MD, FACP, FCCP First Coast Service Options Merck Oncology Memorial Cancer Institute JN MAC
Lourdes Nicola Brian Ramnaraign MD Susan Scherer RN, BSN, Eisai University of Florida OCN RN Cancer Guides Steven Noga MD Patty Rea Takeda Oncology Lilly Oncology Cynthia Schindele Lockheed Martin Cesar Ochoa MD Azure Reese Mayo Clinic Florida Exelixis Kathleen Schnider Cancer Care Centers of Patrick Ossi Eric Reyes Brevard Eisai Amgen Michael Schnider Angelia Palahunik Amy Riley Cleveland Clinic Florida Hospital Todd Schonherz Florida Cancer Specialists Kimberly Patton George Rodriguez Bristol-Myers Squibb Lexicon Pharmaceuticals Brad Scott Amgen Katie Pell Ramon Rodriguez Amgen Pfizer Oncology Lisa Shelar RHIT 21st Century Oncology Heather Peterson Roberto Rodriguez AbbVie Kite Pharma Jennifer Sibley ARNP Bristol-Myers Squibb Sean Phelps Brittany Rogers MD Genentech University of Florida Collin Sinclair Pharmacyclics Kathy Pickens Joseph Rosenblatt MD Foundation Medicine University of Miami Dorimar Siverio-Minardi MPH, MBA, CMPE Glynda Pineres MHA Bhuvana Sagar MD Moffitt Cancer Center Memorial Cancer Institute Cigna
(Current as of April 25, 2018) Business of Oncology Attendees - Continued Glen Smith Susan Unruh Oncology Supply Astellas
Kimberly Smith Tim Valencic AstraZeneca Seattle Genetics
Ileana Sosa Magali Van den Bergh MD Boehringer Ingelheim Moffitt Cancer Center
Curtis Sosnowski Melissa Villanueve Astellas Pfizer Oncology
Jim Steinburg Alton Wallace IPSEN Bayer
Amanda Stephens DO Andrea Warren-Smith Florida Hospital Bristol-Myers Squibb
Shelly Suarez Karen White MSN, RN Bayer Genentech
Winston Tan MD Jon Whiteside Mayo Clinic Florida Eisai
Katie Tarbet Jacqueline Wiley Lilly Oncology Sysmex-Inostics
Megan Taylor RN, BSN Lucretia Willis Parrish Medical Center Florida Hospital
Rayshida Taylor Clayton Wright Bristol-Myers Squibb Takeda Oncology
Yvonne Taylor-Rhoads RN, Jeff Wyatt MSN Sun Pharma Broward Health Coral Springs Scott Yohe NanoString Technologies Cynthia Terrano CPA, BS Moffitt Cancer Center Pam Yurcisin RN Celgene Ken Tingley Pharmacyclics Katie Zacher MBA Florida Hospital Cancer Sierra Tomlinson Institute Florida Cancer Specialists Eliott Zarett Jeffery Trudel Merck Oncology Incyte
Elizabeth Turner Amgen
Dave Tyson Seattle Genetics
(Current as of April 25, 2018)
The Florida Society of Clinical Oncology FLASCO was formed as a statewide 501(c) (3) nonprofit organization committed to facilitating and promoting multidisciplinary efforts to improve patient care in Florida. FLASCO continues to make strides in promoting excellence in care of patients afflicted with cancer and hematologic disorders and leads efforts to respond to policies and legislation that threaten to compromise patient access to quality cancer care. FLASCO is gaining momentum as more professionals use us as the catalyst to develop partnerships, share knowledge, and stand together to demonstrate strength and determination to move forward in the battle against cancer. FLASCO will continue to be recognized as a nationally respected state professional society as we stand together as “the Voice of Oncology in Florida”.
Thank YOU for Attending